From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

Vision loss is a growing concern in India, especially macular degeneration - a common eye condition. Once known to be ...

Surrozen (SRZN) announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

Opthea Ltd. is considering its options after lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD). The global Coast phase III trial ...

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...

Australia-based Opthea, a biopharma developing therapies for progressive retinal diseases, has announced results from its ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

Biotechnology firm Opthea has warned investors its solvency is in question after the failure of a major clinical trial into ...

Incorporate omega-3s into your diet: Foods like fish have been shown to reduce the risk of macular degeneration. Don’t forget to add a handful of walnuts to your meals as they’re also packed with ...